The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway.
about
Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal DomainThe multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functionsMolecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)PCSK9 prosegment chimera as novel inhibitors of LDLR degradation.Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function.Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.Comparing expression and activity of PCSK9 in SPRET/EiJ and C57BL/6J mouse strains shows lack of correlation with plasma cholesterol.Spore surface proteins of Brevibacillus laterosporus are involved in insect pathogenesis.Proprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: hepatic and extra hepatic functions.Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction.Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblastsThe Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation: A NOVEL MECHANISM CAUSING FAMILIAL HYPERCHOLESTEROLEMIA.Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2).Annexin A2 reduces PCSK9 protein levels via a translational mechanism and interacts with the M1 and M2 domains of PCSK9.PCSK9 as a therapeutic target for cardiovascular disease.An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells.Malaria severity: Possible influence of the E670G PCSK9 polymorphism: A preliminary case-control study in Malian children.Characterisation of de novo mutations in the C-terminal domain of proprotein convertase subtilisin/kexin type 9.
P2860
Q27339783-8E3DB4BD-A42E-4699-8B1C-D1C1A341FFD1Q30541820-54F4ECEB-D701-4DDF-B5A4-F755111C6B57Q34458693-5FABEBCA-90AC-48AE-AC4C-B8BB1447D509Q34723257-EF5EF8B3-E5D4-4065-8C7E-CFA30C490EE2Q34951227-3A0BB03B-4A42-4815-AA6F-070F1D24FE27Q35612555-AC381EE2-528F-4C4B-82E9-19C7D062FE9BQ35883857-42A8AE99-9B47-41D9-B34C-E6EDB3EFA384Q36281706-F65FF7A3-4669-41E2-A680-9B213168B790Q37500677-62EA6D99-CC7C-47C1-9DA6-535A00946A6DQ37678765-21EFE43D-1D51-4FBA-8663-C87020F8D9CFQ38109960-23578DEF-EF46-4584-B5E8-D37E21DAB281Q38253151-40D7B933-C29D-4CA9-93EF-FAB65BA138A0Q38855416-F6159177-CFF3-499C-9116-A052EFC8F6A8Q39030028-BAF623BE-089C-42C8-AFBD-CCC63A9AB1CAQ39051108-DFAEFBF6-F01B-4786-9432-9F230FD00886Q39080645-70F5A1A4-8B20-4C4C-AE25-9A7E9C364EF5Q39795723-C08BFCCE-EB13-4436-BBF4-293EBFC24F18Q41020560-8A4675EA-8E1E-40CB-8ECA-4DF539C67863Q41822823-59EB6DBD-3AA8-4E9D-A312-968767E9A4BFQ45401315-3A2CCD7B-E752-49EB-963B-3C1D045F5324Q49980103-A1753268-E69A-4639-9E48-48D161935903Q53298782-20CA0674-AA39-4175-890F-1AEEB12E1F3D
P2860
The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The M2 module of the Cys-His-r ...... or (LDLR) degradation pathway.
@en
type
label
The M2 module of the Cys-His-r ...... or (LDLR) degradation pathway.
@en
prefLabel
The M2 module of the Cys-His-r ...... or (LDLR) degradation pathway.
@en
P2860
P356
P1476
The M2 module of the Cys-His-r ...... or (LDLR) degradation pathway.
@en
P2093
Robert Day
Yascara Grisel Luna Saavedra
P2860
P304
43492-43501
P356
10.1074/JBC.M112.394023
P407
P577
2012-10-26T00:00:00Z